Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the cost-effectiveness of zanubrutinib versus rituximab-based chemoimmunotherapy in Waldenström’s macroglobulinemia. Dr Castillo comments on data from the ASPEN trial (NCT03053440) and on the importance of analyzing cost-effectiveness. Touching on time to treatment failure, drug acquisition, cost of routine care and terminal care, Dr Castillo concludes that zanubrutinib appears to be cost-effective compared with ibrutinib for the treatment of Waldenström’s macroglobulinemia patients. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.